Back

MAIA presents next-generation telomere-targeting cancer drug candidates at IRT 2026

Verifying
  • MAIA presented second-generation telomere-targeting drug candidates at IRT 2026 in Barcelona.
  • Next-generation candidates combine ateganosine with a complementary DNA-targeting agent in one prodrug molecule.
  • Ateganosine is in clinical development for second- or later-line NSCLC treatment.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.